Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 44

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 44
---
ations such as arteriovenous fistulas. It is used to dye blood vessels in the neurovascular system to permanently block blood flow to aneurysms or other vascular malformations, or for arterial and venous embolization in peripheral vessels.

Since 2015, RMC has also distributed neuro-intervention medical
device equipment manufactured by Penumbra Inc. RMC’s distribution agreement with Penumbra Inc. for the resale of its reperfusion
catheter, neuron delivery catheter and related tubing and canister, expired on June 30, 2024. The parties’ negotiations for
a new (or extended) agreement terminated on November 20, 2024. RMC will not purchase additional Penumbra products. Certain issues,
such as whether RMC may continue to sell its existing inventory of Penumbra products or whether Penumbra will repurchase RMC’s inventory,
have not as yet been resolved. To replace sales of Penumbra products, RMC intends to seek to become the sales representative of other
neuro-intervention medical device equipment manufacturers, as well as expand sales of products offered by companies it currently
represents.

Intellectual Property

Except for trade secrets related to operating a medical product distribution
business, there is no significant intellectual property owned or licensed by RMC.

25

Competition in our Industry

Competition for Product Candidates

We face competition with respect to our current product candidates
and will face competition with respect to future product candidates, from pharmaceutical and biotechnology companies to public and private
research institutions, among others.

If our current and/or our future product candidates do not offer sustainable
advantages over competing products, we may otherwise not be able to successfully compete against current and future competitors.

Our competitors may obtain regulatory approval of their products more
rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize
our product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly
or have a better safety profile than our products and these competitors may also be more successful than us in manufacturing and marketing
their products.

The most common methods of treating patients with cancer are surgery,
radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy or a combination of such methods. There
are a variety of available drug therapies marketed for cancer. In many cases, these drugs are administered in combination to enhance efficacy.